CAPR
NASDAQ · Biotechnology
Capricor Therapeutics Inc
$29.83
+0.23 (+0.78%)
CAPR News3 articles
BioCardia Surges on FDA Minutes Showing CardiAMP Trial Can Support PMA
BioCardia shares surged 52% to $1.40 after FDA meeting minutes confirmed its CardiAMP HF II trial may support a PMA for heart-failure cell therapy, bucking a weak biotech sector.
Market Movers: RELX, Capricor, and Global Tensions Shape Trading
RELX drops 8.8% in a week, Capricor soars 387% annually, US-Iran tensions drive crude oil volatility, and other key market movers on May 10, 2026.
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.